Stefan Zeuzem - Articles and news items

Gilead logo

Gilead announces new sustained viral response data for Sofosbuvir based regimens in genotype 3-infected Hepatitis C patients

Industry news / 2 November 2013 / Creston Health

“The VALENCE results demonstrate the high efficacy of a 24-week, sofosbuvir-based, interferon-free treatment regimen for genotype 3 HCV patients…”

Boehringer Ingelheim logo

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease

Industry news, News / 10 November 2012 / Boehringer Ingelheim

Pivotal Phase III interferon-free study being initiated following positive Phase IIb results…

Novartis logo

Novartis first-in-class antiviral DEB025 achieved sustained viral response

Industry news, News / 31 March 2011 / Novartis

Novartis announced that a Phase II study with the first-in-class antiviral DEB025 met its primary endpoint for achieving viral cure…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...